TABLE 4.
Risk of cancer according to duration of levothyroxine exposure
| Cancer | Adjusted odds ratio a (95% CI) | P‐trend | |
|---|---|---|---|
| 60‐<365 d | ≥365 d | ||
| Overall | 1.467 (1.405‐1.532) | 1.529 (1.470‐1.590) | <.0001** |
| Esophageal | 0.699 (0.398‐1.229) | 0.898 (0.540‐1.495) | .42 |
| Gastric | 0.971 (0.752‐1.256) | 1.456 (1.141‐1.857) | .01 |
| Colorectal | 1.122 (0.997‐1.262) | 1.165 (1.034‐1.312) | .007* |
| Liver | 0.819 (0.698‐0.962) | 1.187 (1.014‐1.389) | .005* |
| Pancreatic | 1.327 (0.982‐1.793) | 1.210 (0.855‐1.711) | .10 |
| Lung | 1.146 (1.001‐1.311) | 1.307 (1.143‐1.496) | <.0001** |
| Skin | 1.172 (0.878‐1.565) | 1.679 (1.295‐2.176) | <.001** |
| Female breast | 1.219 (1.105‐1.346) | 1.257 (1.122‐1.409) | <.0001** |
| Cervical | 0.724 (0.557‐0.943) | 0.784 (0.594‐1.035) | .01 |
| Prostate | 1.217 (0.944‐1.567) | 1.299 (1.020‐1.655) | .03 |
| Bladder | 1.226 (0.943‐1.593) | 1.228 (0.955‐1.579) | .08 |
| Kidney | 1.071 (0.797‐1.439) | 1.222 (0.923‐1.618) | <.0001** |
| Brain | 1.831 (1.277‐2.625) | 1.965 (1.395‐2.769) | <.0001** |
Abbreviation: CI, confidence interval.
a
Odds ratio adjusted for age, gender, comorbid conditions, age‐adjusted Charlson comorbidities index scores, and other drugs in Table 1.
*
P < .01; **P < .001.